Management of metastatic prostate cancer

Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate

1941 • 3,235 citations

Cancer statistics, 1997

1997 • 2,045 citations

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1996 • 1,584 citations

A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma

1989 • 1,494 citations

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1997 • 666 citations

The Value of Serum Prostate Specific Antigen Determinations Before and after Radical Prostatectomy

1989 • 534 citations

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.

1993 • 417 citations

Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases

1994 • 416 citations

Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients

1995 • 276 citations

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.

1997 • 274 citations

In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived From Prostate-Specific Antigen

1997 • 267 citations

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III eortc trial (30853)

1993 • 259 citations

Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)

1989 • 214 citations

Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

1997 • 206 citations

Strontium 89 Therapy for the Palliation of Pain Due to Osseous Metastases

1995 • 190 citations

The Clinical Usefulness of Serum Prostate Specific Antigen After Hormonal Therapy of Metastatic Prostate Cancer

1992 • 175 citations

RANDOMISED CONTROLLED STUDY OF ORCHIDECTOMY VS LONG-ACTING D-TRP-6-LHRH MICROCAPSULES IN ADVANCED PROSTATIC CARCINOMA

1985 • 171 citations

THE QUESTION OF CASTRATION FOR ENLARGED PROSTATE

1896 • 148 citations

Independent Prognostic Factors in Patients With Metastatic (Stage D2) Prostate Cancer

1991 • 138 citations

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer

1995 • 123 citations

Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036.

1994 • 90 citations

In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines

1996 • 81 citations

HOW IS ANDROGEN-DEPENDENT METASTATIC PROSTATE CANCER BEST TREATED?

1996 • 73 citations

Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer

1997 • 69 citations

Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial.

1993 • 68 citations

A Retrospective Analysis of the Cost Effectiveness of Treatment with Metastron in Patients with Prostate Cancer Metastatic to Bone

1994 • 55 citations

Androgens and prostate cancer: Biology, pathology and hormonal therapy

1997 • 54 citations

Prostate cancer prevention: investigational approaches and opportunities.

1996 • 39 citations

Advanced prostate cancer

1993 • 15 citations

Current challenges of gene therapy for prostate cancer.

1997 • 12 citations